Companies / Industrials
IEX
IDEX Corporation
Industrial Machinery & Supplies & Components
Industrial Machinery & Supplies & ComponentsAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health71
Growth40
Profitability62
Cash generation86
Balance sheet84
Dilution control83
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)8.3%Revenue growth (FY)5.8%Revenue CAGR (3y)2.8%Gross margin44.5%Operating margin20.2%Net margin14.0%Free cash flow margin17.8%R&D / revenue2.0%Stock comp / revenue0.8%Net debt / operating cash flow1.84xCurrent ratio2.86Diluted share count change-0.8%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $2.8B | $3.2B | $3.3B | $3.3B | $3.5B |
| Gross profit | $1.2B | $1.4B | $1.4B | $1.4B | $1.5B |
| Operating income | $637M | $751M | $732M | $677M | $699M |
| Net income | $449M | $587M | $596M | $505M | $483M |
| Operating cash flow | $565M | $557M | $717M | $668M | $680M |
| Capital expenditure | $73M | $68M | $90M | $65M | $64M |
| Free cash flow | $493M | $489M | $627M | $603M | $617M |
| R&D | $50M | $61M | $68M | $67M | $70M |
| Stock-based comp | $20M | $22M | $22M | $26M | $27M |
| Buybacks | $0 | $148M | $24M | $0 | $248M |
| Dividends | $161M | $177M | $191M | $205M | $213M |
| Cash | $855M | $430M | $534M | $621M | $580M |
| Total debt | $1.2B | $1.5B | $1.3B | $2.1B | $1.8B |
| Equity | $2.8B | $3.0B | $3.5B | $3.8B | $4.0B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.